A Comparative Evaluation of the Effects of Saroglitazar and Pioglitazone on Hepatic and Metabolic Parameters in Type 2 Diabetes Mellitus With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Cureus · 2025 · PMC12829429 · PMID 41583325

Europe PMC DOI

hedged sentence

0.0870

closest p · 1.7× alpha

0.0870

boldest claim

The sentences

did not reach statistical significancep = 0.087so close (0.05 < p ≤ 0.1)

HDL levels showed a slight increase in both groups, with a mean rise of 1.44 mg/dL in the saroglitazar arm, but this too did not reach statistical significance (p = 0.087).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.